Transplant-Ineligible NDMM: When to Use a Quadruplet Regimen

Findings from RedirecTT-1 show responses across different dose levels of talquetamab/teclistamab among those with multiple myeloma.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Real-world data show that closer monitoring may be necessary for patients with relapsed/refractory multiple myeloma and baseline renal impairment.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Complete response rate strongly correlated with lower SLiM-CRAB incidence and biochemical progression in those with high-risk smoldering multiple myeloma.

Patients who received the isatuximab combination in the IMROZ trial experienced prolonged MRD-negativity, which correlated with improved PFS.